Streetbeat News

UNCY

Unicycive Therapeutics, Inc.

https://www.unicycive.com

Industry

Biotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Open

0.45

Mkt cap

43M

Volume

1.8M

High

0.47

P/E Ratio

-1.35

52-wk high

1.82

Low

0.42

Div yield

N/A

52-wk low

0.20

Unicycive Therapeutics, Inc. announced its Q3 2024 financial results and provided a business update. The FDA accepted the NDA for OLC with a PDUFA date set for June 28, 2025. The company is planning for a 2025 commercial launch and completed a Phase 1 trial for UNI-494.

Portfolio Pulse from

November 13, 2024 | 12:30 pm

Unicycive Therapeutics announced that the FDA has accepted their NDA for Oxylanthanum Carbonate, a treatment for hyperphosphatemia in dialysis patients, with a PDUFA date set for June 28, 2025. The company is preparing for a commercial launch in 2025.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

Unicycive Therapeutics shares rose following the announcement of poster presentations for Oxylanthanum Carbonate and UNI-494 at the American Society of Nephrology Kidney Week 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:44 pm

Unicycive Therapeutics will present posters on Oxylanthanum Carbonate and UNI-494 at the American Society of Nephrology Kidney Week 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 11:08 am

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) will present new research on its kidney disease therapies at ASN Kidney Week 2024. The company will showcase findings on oxylanthanum carbonate (OLC) and UNI-494, highlighting their potential benefits for patients with chronic kidney disease. Unicycive is seeking FDA approval for OLC, which has shown promising results in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 11:05 am

In Friday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Allakos, and Unicycive Therapeutics, while Akanda, Dogwood Therapeutics, and Nexalin Technology were among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 8:31 pm

HC Wainwright & Co. has reiterated its Buy rating for Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 6:41 pm

Unicycive Therapeutics has completed the Phase 1 study of UNI-494 in healthy volunteers. The results will guide the dosing and scheduling for a potential Phase 2 trial targeting acute kidney injury.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 11:08 am

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 12:00 pm

HC Wainwright & Co. has reiterated its Buy rating for Unicycive Therapeutics, maintaining a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 3:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.